Qbiotics address this with an announcement yesterday ( 13th Oct )
'QBiotics also notes that our company has a strong intellectual property position around this class of molecule being the holder of a number of patent families covering tigilanol tiglate, related analogues and their use in multiple therapeutic indications. Overall, although interesting, this academic work has no impact on our commercial position or plans with tigilanol tiglate.'
